التفاصيل البيبلوغرافية
| العنوان: |
Blood Transfusion and Survival of Children, Adolescent, and Young Adult Patients with Osteosarcoma: A Multicenter Retrospective Cohort Study. |
| المؤلفون: |
Cho, Sukjoo, Fierstein, Jamie L., Khalaf, Racha T., Morrison, John M., Metts, Jonathan |
| المصدر: |
Cancers; Jan2025, Vol. 17 Issue 1, p97, 15p |
| مصطلحات موضوعية: |
RADIOTHERAPY, OSTEOSARCOMA, SURVIVAL, RESEARCH funding, MULTIPLE regression analysis, IFOSFAMIDE, HEMOGLOBINS, RETROSPECTIVE studies, MULTIVARIATE analysis, CANCER chemotherapy, LONGITUDINAL method, KAPLAN-Meier estimator, COMBINED modality therapy, RESEARCH, MEDICAL records, ACQUISITION of data, BLOOD transfusion, PROGRESSION-free survival, OVERALL survival, ADOLESCENCE, CHILDREN, ADULTS |
| مستخلص: |
Simple Summary: Although blood transfusion is generally considered lifesaving, there have been long-standing concerns that it may suppress the anti-cancer immunity of recipients. The aim of our study is to assess the potential effect of transfusion on the survival of children, adolescent, and young adult (CAYA, 39 years old or younger) patients with osteosarcoma, the most common malignant bone tumor. We focused on blood transfusion during chemotherapy before surgery, when the tumor remains bulky with continued risk for metastasis. Our data did not reveal any association between presurgical transfusion and the survival of CAYA patients with osteosarcoma. We detected no specific difference by transfusion type (red blood cells, platelets). Our findings provide reassurance given decades-long discussions about transfusion-related suppression of anti-cancer immunity. Background/Objectives: Prior studies suggest that blood transfusion may adversely affect the survival of patients with cancer via transfusion-related immunomodulation. The objective of our study is to investigate the association between transfusion during neoadjuvant chemotherapy and survival in children, adolescent, and young adult (CAYA, 39 years old or younger) patients with osteosarcoma. Methods: This is a multicenter retrospective cohort study of patients between 2007 and 2022. Our primary exposure was receipt of any blood product in the neoadjuvant period (i.e., neoadjuvant transfusion). The primary outcome of interest was 3-year event-free survival (EFS) calculated using the Kaplan–Meier method, while secondary outcomes of interest included 5-year EFS and 3- and 5-year overall survival (OS). Firth multivariable logistic regression models were constructed to evaluate the adjusted association between transfusion status and 3- and 5-year EFS and OS. Results: In total, 73 patients were included in the analytic sample; among them, 34 received neoadjuvant transfusion. There was no significant difference between transfused and non-transfused groups in race, ethnicity, tumor location, stage at diagnosis, histologic response to neoadjuvant chemotherapy, and receipt of ifosfamide or radiation during initial treatment. The transfusion group included more females (p = 0.02) and lower median hemoglobin at diagnosis (p = 0.002) than the non-transfusion group. EFS and OS did not significantly vary by transfusion status or type. Conclusions: We did not observe an adjusted association between neoadjuvant transfusion and survival in CAYA patients with osteosarcoma. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder